Shots: The P-III TULIP 2 study involves assessing of anifrolumab (300mg, FD, IV) vs PBO in 373 patients in ratio (1:1) for adults with moderate-to-severe SLE and has demonstrated meeting […]readmore
Tags : TULIP 2 Study